On July 29, 2022 Avecho (ASX:AVE) reported that it has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2022 (Press release, Phosphagenics, JUL 29, 2022, View Source [SID1234617118])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key highlights from this period include:

Essential preparation underway for the commencement of Phase III CBD soft-gel program;
High profile exposure for Phase II data trialling the effectiveness of cannabinoids for treating arthritis of the hand, in top tier media and as part of the International Cannabis Research Society (ICRS) Conference in Galway;
Promising business development and partnership discussions ongoing for cannabinoid and broader portfolio of human health products;
Receipt of $1,007,990.22 under the Australian Government’s R&D Tax Incentive Scheme.
Avecho’s cash balance on 30 June was $3.13m.